Charcot-Marie-Tooth症（CMT）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國市場預計將從約 9,500 萬美元成長到約 8.5 億美元（複合年成長率超過 25%）。
• 新興的基因和 RNA 標靶治療方法正在推動成長，導致治療方式從對症治療轉向疾病修正治療。

Charcot-Marie-Tooth症（CMT）概述

Charcot-Marie-Tooth症（CMT）是一組遺傳性周邊神經病變，其特徵是運動神經和感覺神經進行性退化，導致肌肉無力、感覺障礙和功能障礙。此病通常在兒童或青少年期發病，主要症狀包括遠端肌肉無力、足部畸形（例如高弓足）、步態異常和感覺功能減退。

CMT在遺傳上具有異質性，包含多種亞型，這些亞型由不同的分子機制定義。最常見的類型是CMT 1型（去髓鞘化型），主要由PMP22基因重複引起（約佔70-80%的病例）。 CMT 2型（軸索型）通常與MFN2基因突變相關，而X連鎖CMT（CMTX）則涉及GJB1基因突變。其他亞型，包括CMT 4型（體染色體隱性遺傳型）和中間型，則表現出軸索型和去髓鞘化病理的混合特徵。

雖然 CMT 與其他​​一些神經肌肉疾病在臨床表現上有重疊，但它與肌萎縮側索硬化症 (ALS) 等疾病截然不同。目前尚無根治性，治療重點在於多學科支持性治療方法，包括物理治療以改善活動能力和生活品質、矯正器具支援以及症狀治療。

主要亮點

• CMT是一種慢性進行性遺傳性神經病變，其特徵是嚴重的機能障礙。
• 德國的患病人數預計將從約 31,600 人增加到約 33,900 人（年複合成長率：約 0.7%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• NMD Pharma A/S
• Tasly GeneNet Pharmaceuticals Co., Ltd
• Cellatoz Therapeutics, Inc
• ENCell
• Elpida Therapeutics SPC
• Novartis Pharmaceuticals
• Vanda Pharmaceuticals
• Applied Therapeutics, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Charcot-Marie-Tooth (CMT) Market Outlook

Thelansis's "Charcot-Marie-Tooth (CMT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Charcot-Marie-Tooth (CMT) Overview

Charcot-Marie-Tooth disease (CMT) represents a group of inherited peripheral neuropathies characterized by progressive degeneration of motor and sensory nerves, leading to muscle weakness, sensory loss, and functional impairment. The disease typically manifests in childhood or adolescence, with hallmark features including distal muscle weakness, foot deformities (e.g., pes cavus), gait abnormalities, and reduced sensation.

CMT is genetically heterogeneous, with multiple subtypes defined by distinct molecular mechanisms. The most common form, CMT Type 1 (demyelinating), is primarily caused by PMP22 gene duplication (~70-80% of cases). CMT Type 2 (axonal) is frequently associated with mutations in MFN2, while X-linked CMT (CMTX) involves mutations in the GJB1 gene. Additional subtypes, including CMT Type 4 (autosomal recessive) and intermediate forms, exhibit mixed axonal and demyelinating pathology.

Although CMT shares some clinical overlap with other neuromuscular disorders, it is distinct from conditions such as amyotrophic lateral sclerosis (ALS). Currently, there is no curative therapy, and management focuses on multidisciplinary supportive care, including physiotherapy, orthotic support, and symptomatic treatment to improve mobility and quality of life.

Key Highlights

• CMT is a chronic, progressive hereditary neuropathy with significant functional impairment
• Germany prevalence expected to increase from ~31.6K to ~33.9K (~0.7% CAGR)

Market Overview

• Germany market projected to grow from ~$95M to ~$850M (~25%+ CAGR)
• Growth driven by emerging gene and RNA-targeted therapies, shifting from supportive care to disease-modifying approaches

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• NMD Pharma A/S
• Tasly GeneNet Pharmaceuticals Co., Ltd
• Cellatoz Therapeutics, Inc
• ENCell
• Elpida Therapeutics SPC
• Novartis Pharmaceuticals
• Vanda Pharmaceuticals
• Applied Therapeutics, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)